Overview

• The restructuring will remove about 15% of the global workforce and seeks US$500 million to US$550 million in annual savings over the next three years.
• Operational changes include combining the commercial and medical arms of the plasma and iron‑deficiency businesses and closing 22 U.S. plasma centers over the next 12 months.
• CSL plans to demerge its Seqirus influenza‑vaccine unit into a separately listed ASX company led by former Seqirus president Gordon Naylor, subject to third‑party consents, regulatory approvals and a shareholder vote, with timing targeted for 2026.
• The company guided to a one‑off pre‑tax restructuring charge of US$700 million to US$770 million in the 2026 financial year.
• Shares fell sharply after the announcement, with opening trade down about 9.5%, even as full‑year revenue rose 5% and underlying profit increased roughly 14%, and management said guidance assumes no impact from any potential U.S. pharmaceutical tariffs.